Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio’s proprietary All H2L2 transgenic Harbour Mice platform to discover antibodies, alongside their application as part of antibody-drug conjugate (ADC) technology to develop ADC products. Kelun-Biotech will pay an undisclosed amount of upfront payment, milestone payment, and sales-based royalties.
Nona Bio’s Services and Harbour Mice Platform
Nona Bio provides diversified one-stop antibody and antibody-related discovery services such as antigen preparation, animal immunity, single B cell screening, antibody development and engineering, and pharmaceutical and pharmacological evaluations. The Harbour Mice platform allows for the generation of fully human monoclonal antibodies in the classical two light and two heavy chain (H2L2) format and heavy chain only (HCAb) format.
Kelun-Biotech’s Focus and Pipeline
Kelun-Biotech, focused on oncology, autoimmune diseases, inflammation, metabolic diseases, and more, boasts upwards of 33 novel programs, including 14 in the clinics in China and 3 in the US.-Fineline Info & Tech
